Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Astec Lifesciences's annualized net income for the quarter that ended in Mar. 2026 was ₹-310 Mil. Astec Lifesciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹3,659 Mil. Therefore, Astec Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -8.48%.
The historical rank and industry rank for Astec Lifesciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ASTEC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -48.03 Med: 17.41 Max: 26.08
Current: -25.12
During the past 13 years, Astec Lifesciences's highest Return-on-Tangible-Equity was 26.08%. The lowest was -48.03%. And the median was 17.41%.
NSE:ASTEC's Return-on-Tangible-Equity is ranked worse than 90.32% of 248
companies
in the Agriculture industry
Industry Median: 7.89
vs NSE:ASTEC: -25.12
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Astec Lifesciences Return-on-Tangible-Equity Related Terms
Astec Lifesciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Astec Lifesciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ASTEC vs CTVA, CF, MOS: Return-on-Tangible-Equity Comparison
For the Agricultural Inputs subindustry, Astec Lifesciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astec Lifesciences Return-on-Tangible-Equity vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Astec Lifesciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Astec Lifesciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -8.48% mean?
Astec Lifesciences (NSE:ASTEC) has a Return-on-Tangible-Equity of -8.48% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Astec Lifesciences and its competitors. According to the industry distribution chart, Astec Lifesciences ranks #224 out of 248 companies in the Agriculture industry, placing it in the top 90.3%.
Is Astec Lifesciences' Return-on-Tangible-Equity too high?
Astec Lifesciences' current Return-on-Tangible-Equity is -8.48%. Based on the distribution chart, Astec Lifesciences ranks #224 out of 248 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Astec Lifesciences has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' Return-on-Tangible-Equity compare to CTVA and CF?
According to the Agriculture industry distribution chart, Astec Lifesciences ranks #224 out of 248 companies for Return-on-Tangible-Equity. This places Astec Lifesciences in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Agriculture company?
The median Return-on-Tangible-Equity among Agriculture companies is 7.89, based on 248 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Astec Lifesciences and its competitors. For the Agriculture industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astec Lifesciences's current Return-on-Tangible-Equity is -8.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (NSE:ASTEC) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹986.09, compared to a current price of ₹699.40 — trading 29.1% below its estimated fair value. The current Return-on-Tangible-Equity is -8.48%. Astec Lifesciences' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Astec Lifesciences (NSE:ASTEC), the current Return-on-Tangible-Equity is -8.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astec Lifesciences (NSE:ASTEC) Overvalued in 2026?
Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued.
The current stock price of ₹699.40 is trading 29.1% below its estimated GF Value™ of ₹986.09.
GuruFocus considers Astec Lifesciences to be Modestly Undervalued.
Key valuation signals for NSE:ASTEC:
Return-on-Tangible-Equity: -8.48%
GF Value™: ₹986.09 vs. price of ₹699.40 (29.1% below fair value)
No single metric tells the full story. See the NSE:ASTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
79GF Score
Get the complete analysis for NSE:ASTEC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTEC has been successfully added to your 
